Table 3.
Major Diffferences in Dutasteride and Finasteride, the 2 Approved 5α-Reductase Inhibitors*
| Dutasteride | Finasteride | |
|---|---|---|
| Dosage, mg/d | 0.5 | 5.0 |
| Half-life (d) | 35 | 0.3 |
| 5α-reductase inhibition | Type 1 and 2 | Type 2 |
| DHT suppression (%) | 90 | 70 |
| Prostate volume reduction (y 2, %) | 27 | 20 |
| Symptom decrease, 2 y (IPSS points) | 3.8 | 3.1 |
| Uroflow increase, 2 y (Qmax, cc/sec) | 1.9 | 1.8 |
| Risk reduction (AUR, y 4, %) | 57 | 57 |
| Side effects (ED, libido, ejaculatory | 10–15 | 10–15 |
| disorders, breast; %)† | ||
| Cost (AWP, 1 m Rx, 2/03; $) | 75 | 80 |
*
These data reflect the author’s impression based on information published in the 2003 package inserts of both drugs.
†
Percent of patients reporting 1 or more of these side effects during first year of study.
DHT, dihydrotestosterone; IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; AUR, acute urinary retention; ED, erectile dysfunction; AWP, average wholesale price.